 |
 |
|
 |
|
Welcome to edition #1 of the SWOG Update.
For all members and friends of the Southwest Oncology Group, the SWOG Update will keep you informed of what's happening with the Group. News to report? Send it to communications@swog.org.
|
|
|
|
 |
| |
 |
|
 |
|
Why we do what we do
Our mission is straightforward: to make progress in the prevention and cure of cancer through clinical research. Our research objectives define how we work to accomplish our mission.
[more]
|
|
|
|
 |
 |
|
|
|
You, your colleagues, and your cooperative group in the media ...
|
|
|
|
|
|
 |
|
|
|
Open for business: SWOG Clinical Trials Initiative
-- by Laura Jacquez, administrative and financial coordinator, SWOG Clinical Trials Initiative (SWOG-CTI)
What is SWOG-CTI?
SWOG - Clinical Trials Initiative, or SWOG-CTI, is a 501(c)(3) limited liability company housed within The Hope Foundation, the philanthropic arm of the Southwest Oncology Group (SWOG).
Our mission at SWOG-CTI is identical to SWOG’s: to make progress in the prevention and cure of cancer through clinical research. We were created as an independent non-profit to allow the Group to receive and distribute supplemental funds from non-federal sources to support that mission.
In the past, if your institution received such supplemental funds to support SWOG clinical trials, those funds came to you from the SWOG Operations Office in San Antonio, Texas. This funding is now managed by SWOG-CTI out of Ann Arbor, Michigan.
To receive funds from SWOG-CTI
In January 2009, we sent the principal investigator (PI) for each SWOG site a new SWOG-CTI purchase service agreement (PSA). Sites that wish to continue to receive industry funding for participation in SWOG trials must complete this new PSA, which is in addition to a site’s federal-funding PSA already in place with SWOG. Approximately 50% of SWOG sites have responded thus far.
If your institution hasn’t yet responded but would like to work with SWOG-CTI, have your PI verify the list of investigators that accompanied the new PSA and return a signed copy of the PSA to the address provided. If you have not received a PSA, please contact me at ljacquez@swogcti.org or (734) 998-6890.
Payment Scenarios
At this time, there are several scenarios in which SWOG-CTI will distribute funds to investigators:
- For SWOG-initiated clinical trials with National Cancer Institute (NCI) funding, SWOG-CTI may obtain and distribute additional funding. This would be a supplement to cover clinical trial costs incurred by an investigator or institution, and would be in addition to the NCI funding an investigator gets from SWOG’s U10 grant or an institutional U10 grant. Typical credits would apply to patient registration.
- SWOG-CTI may be the sole sponsor of a SWOG clinical trial. This would be a study the NCI chose not to fund, and therefore wouldn’t be eligible for per capita reimbursement or credit from U10 grants. In such a situation, we would provide an investigator or institution the entire payment for clinical trial registration.
- SWOG-CTI may distribute research-related funds to SWOG investigators for their contributions to clinical trial or translational medicine components unrelated to their institution’s trial enrollment. An example of this scenario would be payments for specimen analysis funded through non-federal sources.
S0702 leads the way
The first SWOG-CTI funded study is S0702, "A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment," which opened mid-December 2008. Funding for S0702 is available through cancer control credits for SWOG CCOP sites, and through pharmaceutical funding via SWOG-CTI. As is the case with all SWOG trials, once a study is open, details regarding payment can be found in the funding memorandum via swog.org.
If you have questions or comments about SWOG-CTI, we’d love to hear from you. Please contact me, Laura Jacquez, administrative and financial coordinator, at ljacquez@swogcti.org or at (734) 998-6890.
|
|
|
|
 |
|
